ketoconazole has been researched along with Bone Neoplasms in 16 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
Bone Neoplasms: Tumors or cancer located in bone tissue or specific BONES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ketoconazole has been used with success to treat disseminated intravascular coagulation and acute spinal cord compression syndromes associated with metastatic prostatic adenocarcinoma." | 8.79 | Ketoconazole-induced adrenal crisis in a patient with metastatic prostatic adenocarcinoma: case report and review of the literature. ( Ahmann, FR; Dalkin, BL; Sarver, RG, 1997) |
| "This study examined the effect of ketoconazole on viability, apoptosis, mitogen-activated protein kinases (MAPKs) and Ca(2+) levels in MG63 osteosarcoma cells." | 7.75 | Ketoconazole-induced JNK phosphorylation and subsequent cell death via apoptosis in human osteosarcoma cells. ( Chang, HT; Cheng, JS; Huang, CC; Jan, CR; Lin, KL; Lu, YC; Tsai, JY, 2009) |
| "We report the use of ketoconazole to control disseminated intravascular coagulation due to prostatic carcinoma." | 7.67 | Emergency treatment with ketoconazole in disseminated intravascular coagulation due to metastatic prostatic carcinoma. ( Bhadoria, DP; Malhotra, KK; Mehta, S; Mittal, D; Mukhopadhyay, DK; Rao, YV, 1989) |
| "Ketoconazole has been used with success to treat disseminated intravascular coagulation and acute spinal cord compression syndromes associated with metastatic prostatic adenocarcinoma." | 4.79 | Ketoconazole-induced adrenal crisis in a patient with metastatic prostatic adenocarcinoma: case report and review of the literature. ( Ahmann, FR; Dalkin, BL; Sarver, RG, 1997) |
| "This study examined the effect of ketoconazole on viability, apoptosis, mitogen-activated protein kinases (MAPKs) and Ca(2+) levels in MG63 osteosarcoma cells." | 3.75 | Ketoconazole-induced JNK phosphorylation and subsequent cell death via apoptosis in human osteosarcoma cells. ( Chang, HT; Cheng, JS; Huang, CC; Jan, CR; Lin, KL; Lu, YC; Tsai, JY, 2009) |
| "We report the use of ketoconazole to control disseminated intravascular coagulation due to prostatic carcinoma." | 3.67 | Emergency treatment with ketoconazole in disseminated intravascular coagulation due to metastatic prostatic carcinoma. ( Bhadoria, DP; Malhotra, KK; Mehta, S; Mittal, D; Mukhopadhyay, DK; Rao, YV, 1989) |
| "Twenty-two patients who had progressive metastatic prostatic carcinoma (Stage D2) despite androgen-deprivation therapy (bilateral orchiectomy, 10 cases; bilateral orchiectomy followed by diethylstilbestrol, 7 cases; diethylstilbestrol, 3 cases; combined megestrol acetate and low-dose estrogen, 2 cases) were treated with ketoconazole." | 3.67 | Ketoconazole therapy for hormonally refractive metastatic prostate cancer. ( Babaian, RJ; Johnson, DE; Tenney, D; von Eschenbach, AC; Wishnow, KI, 1988) |
| " Overall, the chemotherapy combined with Sr-89 was well tolerated." | 2.73 | Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer. ( Amato, RJ; Henary, H; Hernandez-McClain, J, 2008) |
| "Ketoconazole (KT) has demonstrated activity in androgen independent prostate cancer (AIPC)." | 2.71 | A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. ( Arlen, P; Chen, CC; Cox, MC; Cremers, S; Dahut, WL; Figg, WD; Gulley, J; Jones, E; Liewehr, DJ; Liu, Y; Parr, A; Steinberg, SM; Yang, X; Zhai, S, 2005) |
| "We report the case of a patient with prostate cancer who develops mediastinal lymphadenopathy, pulmonary nodules and cutaneous metastases 8 years after the diagnosis." | 1.34 | [Mediastinal lymph nodes during the course of a metastatic prostate cancer]. ( Aguilera Tubet, C; Ballestero Diego, R; Roca Edreira, A; Villanueva Peña, A; Zubillaga Guerrero, S, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (25.00) | 18.7374 |
| 1990's | 3 (18.75) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aggarwal, R | 1 |
| Halabi, S | 1 |
| Kelly, WK | 1 |
| George, D | 1 |
| Mahoney, JF | 1 |
| Millard, F | 1 |
| Stadler, WM | 1 |
| Morris, MJ | 1 |
| Kantoff, P | 1 |
| Monk, JP | 1 |
| Carducci, M | 1 |
| Small, EJ | 1 |
| Amato, RJ | 2 |
| Hernandez-McClain, J | 1 |
| Henary, H | 1 |
| Lin, KL | 1 |
| Huang, CC | 1 |
| Cheng, JS | 1 |
| Tsai, JY | 1 |
| Lu, YC | 1 |
| Chang, HT | 1 |
| Jan, CR | 1 |
| Miller, K | 1 |
| Figg, WD | 1 |
| Liu, Y | 1 |
| Arlen, P | 1 |
| Gulley, J | 1 |
| Steinberg, SM | 1 |
| Liewehr, DJ | 1 |
| Cox, MC | 1 |
| Zhai, S | 1 |
| Cremers, S | 1 |
| Parr, A | 1 |
| Yang, X | 1 |
| Chen, CC | 1 |
| Jones, E | 1 |
| Dahut, WL | 1 |
| Scholz, M | 1 |
| Jennrich, R | 1 |
| Strum, S | 1 |
| Brosman, S | 1 |
| Johnson, H | 1 |
| Lam, R | 1 |
| Hobdy, EM | 1 |
| Shafi, NQ | 1 |
| Kummar, S | 1 |
| Argirovic, Dj | 1 |
| Roca Edreira, A | 1 |
| Aguilera Tubet, C | 1 |
| Villanueva Peña, A | 1 |
| Ballestero Diego, R | 1 |
| Zubillaga Guerrero, S | 1 |
| Sarver, RG | 1 |
| Dalkin, BL | 1 |
| Ahmann, FR | 1 |
| Ellerhorst, JA | 1 |
| Tu, SM | 1 |
| Finn, L | 1 |
| Millikan, RE | 1 |
| Pagliaro, LC | 1 |
| Jackson, A | 1 |
| Logothetis, CJ | 1 |
| Huben, RP | 1 |
| Eichenberger, T | 1 |
| Trachtenberg, J | 1 |
| Bhadoria, DP | 1 |
| Mukhopadhyay, DK | 1 |
| Mehta, S | 1 |
| Mittal, D | 1 |
| Rao, YV | 1 |
| Malhotra, KK | 1 |
| Johnson, DE | 1 |
| Babaian, RJ | 1 |
| von Eschenbach, AC | 1 |
| Wishnow, KI | 1 |
| Tenney, D | 1 |
| Flamm, J | 1 |
| Sagaster, P | 1 |
| Teich, G | 1 |
| Köhn, H | 1 |
| Miksche, M | 1 |
2 reviews available for ketoconazole and Bone Neoplasms
| Article | Year |
|---|---|
[Castration resistant prostate cancer 2011].
Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Agents, Hormo | 2011 |
Ketoconazole-induced adrenal crisis in a patient with metastatic prostatic adenocarcinoma: case report and review of the literature.
Topics: Adenocarcinoma; Adrenal Gland Diseases; Aged; Bone Neoplasms; Humans; Ketoconazole; Male; Prostatic | 1997 |
6 trials available for ketoconazole and Bone Neoplasms
| Article | Year |
|---|---|
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (
Topics: Aged; Androgen Antagonists; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antineoplastic Com | 2013 |
Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Combined Chemotherapy Pro | 2008 |
A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases.
Topics: Aged; Alendronate; Bone Neoplasms; Drug Therapy, Combination; Humans; Ketoconazole; Male; Middle Age | 2005 |
Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer.
Topics: Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Neopl | 1997 |
Hormone therapy of prostatic bone metastases.
Topics: Actuarial Analysis; Androgen Antagonists; Bone Neoplasms; Combined Modality Therapy; Diethylstilbest | 1992 |
Effects of high-dose ketoconazole on patients who have androgen-independent prostatic cancer.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Neoplasms; Clinical Trials as Topic; Drug Administr | 1989 |
8 other studies available for ketoconazole and Bone Neoplasms
| Article | Year |
|---|---|
Ketoconazole-induced JNK phosphorylation and subsequent cell death via apoptosis in human osteosarcoma cells.
Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Cytotoxins; Extra | 2009 |
Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone.
Topics: Aged; Androgens; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; | 2005 |
Prostate cancer metastasis to supraclavicular lymph node.
Topics: Acid Phosphatase; Adenocarcinoma; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Prot | 2004 |
An evaluation of high-doses ketoconazole with hydrocortisone substitution in hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Dis | 2005 |
[Mediastinal lymph nodes during the course of a metastatic prostate cancer].
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Bon | 2007 |
Emergency treatment with ketoconazole in disseminated intravascular coagulation due to metastatic prostatic carcinoma.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Disseminated Intravascular Coagulation; Emergencies; Humans; K | 1989 |
Ketoconazole therapy for hormonally refractive metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Androgens; Bone Neoplasms; Carcinoma; Combined Modality Therapy; Diethylsti | 1988 |
[High dosage ketoconazole therapy in the treatment of advanced prostatic cancer].
Topics: Aged; Bone Neoplasms; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Ketoconazole; Mal | 1988 |